Akzo N.v.

Akzo Nobel N.v.

Other

Per Immune Holdings, Inc.

Intracel Resources LLC

Michael G Hanna, Jr

Martin V Haspel

Herbert C Hoover, Jr

Nicholas Pomato

Ebo S Bos

Alvaro Morales

Sandra M Butler

Janet H Ransom

Barry J Kobrin

Michael L Berman

Marie E Dembinsky

Leona C Peters

Ebo Bos

Autologous anti-cancer vaccines and methods of manufacture and treatment are provided, including expansion of individual patient-derived tumor cells in an immune-compromised animal(s) to attain, quantitatively and qualitatively, sufficient material for efficacious vaccine production and utilization, to elicit an immune response against micrometastases and/or recurrence in the individual patient following tumor excision.

Autologous tumor vaccines and methods

This invention relates to methods of removing bioburden from an aggregate of cells to obtain sterile cells that remain viable and immunogenic for the production of vaccines. This invention further relates to a method of eliciting an immune response to prevent a recurrence of metastases that involves preparing and administering a sterile vaccine derived from solid tumors. The vaccine is prepared by excising a solid tumor from a cancer patient, digesting the tumor cells with an enzyme to obtain dissociated cells, irradiating the dissociated cells to render the cells non-tumorigenic, and sterilizing the cells.

Sterile immunogenic non-tumorigenic tumor cell compositions and methods

This invention relates to the epitopes to which monoclonal antibody 88BV59 and antibody 16.88 react. These antibodies were produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigens. Both epitopes are found on the same antigen in tumor tissue. These epitopes can be used in both diagnostic procedures and therapy for human cancers.

Tumor associated epitope

The present invention comprises the epitope recognized by the human monoclonal antibody 28A32, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and human MCA 28A32. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.

CTAA 28A32, the antigen recognized by MCA 28A32

This invention relates to a method of cancer therapy for treating human patients with resectable solid tumors to inhibit recurrence and formation of metastases, comprising surgically removing tumor tissue from a human cancer patient, treating the tumor tissue to obtain tumor cells, irradiating the tumor cells to be viable but non-tumorigenic, preparing a vaccine comprising about 10.sup.7 viable but non-tumorigenic tumor cells per dose and injecting the vaccine intradermally into the human patient after the patient's immune system has recovered from surgery.

Active specific immunotherapy

This invention relates to monoclonal antibody 88BV59 produced by B-cell lines derived from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Tumor associated monoclonal antibodies

This invention relates to human monoclonal antibody 81AV78 produced by a transformed B-cell line, having ATCC accession number CRL 10750 derived from B-cells of cancer patients actively immunized with autologous tumor antimen. This monoclonal antibody can be used in both diagnostic procedures and therapy for human cancers.

Tumor associated monoclonal antibody 81AV/78

The present invention comprises the epitope recognized by the human monoclonal antibody 16-18, the human tumor antigen containing this epitope, which we have identified, isolated and characterized, and anti-idiotypic antibodies to human MCA 16-88, which comprise the same epitope. The invention also relates to the use of antibodies to the antigen containing this epitope for diagnosis and monitoring of treatment of cancer and to the use of this antigen in the preparation of vaccines to elicit an immune response similar to that obtained against tumor cells containing this epitope.

Antigen recognized by MCA 16-88

A human monoclonal antibody having specificity for an epitope in a tumor associated antigen, said antibody produced by a cell line selected from the group consisting of Co6a3-1 (HB8493), Co7a4 (HB8494), Co28A32 (HB9380), Co16-86 (HB8496), and Co16-88 (HB8495).

Tumor specific monoclonal antibodies

A device for delivering medication into a human body, comprising a catheter having proximate and distal ends, and first and second lumina extending substantially the entire length of the catheter. A first opening in the catheter near its distal end drains fluid from a body when the catheter is inserted therein. There is a second opening in the catheter between the first opening and the distal end of the catheter. The second opening is fluidly connected with the second lumen. A diaphragm is located adjacent to the second opening for blocking off the second opening from the second lumen, and the diaphragm is burstable by a predetermined pressure for unblocking the second opening for fluidly connecting it with the second lumen. Thus, medications can be safely administered without the possibility of premature contact of the medication with the body. The catheter is particularly well suited to the administration of toxic substances such as BCG vaccine into the bladder of bladder cancer patients.

Urethral catheter and catheterization process

A method for producing a human B-lymphocyte that is able to grow in cell culture and produces human monoclonal antibodies having binding specificity for tumor-associated antigens by exposing a human B-lymphocyte to a tumor cell antigen in a vaccine containing viable human tumor cells that have been made non-tumorigenic, and immortalizing the exposed B-lymphocyte by exposing to a transforming agent for sufficient time to transform the B-lymphocyte.

Hybridoma cell lines and transformed B-cell lines are derived from B-cells of cancer patients actively immunized with autologous tumor antigens and used to produce monoclonal antibodies having specificity for tumor-associated antigens. The monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Tumor associated monocoloal antibodies derived from human B-cell line

Monoclonal antibodies produced by hybridoma or transformed B-cell lines deriveed from B-cells of cancer patients actively immunized with autologous tumor antigen. These monoclonal antibodies can be used in both diagnostic procedures and therapy for human cancers.

Growing community of inventors

Frederick, MD, United States of America

Michael G Hanna, Jr